More than a century after daily insulin injections became the cornerstone of diabetes care, India now sees its first weekly insulin alternative. Danish pharmaceutical giant Novo Nordisk unveiled Awiqli (insulin icodec), a basal insulin designed for adults with both Type‑1 and Type‑2 diabetes, marking a significant shift in treatment paradigms.

Historical Context

Since the discovery of insulin in the early 1920s, patients worldwide have been accustomed to daily needle‑pricks. India, home to an estimated 101 million diabetics and another 136 million pre‑diabetics, represents one of the largest disease burdens globally. Fear of daily injections often delays insulin initiation by seven to nine years, undermining glycaemic control.

What Novo Nordisk Claims

Clinical trials involving over 4,000 adults—including Indian participants—showed that Awiqli achieved superior HbA1c reductions compared with conventional daily basal insulins. By reducing the injection frequency from 365 to just 52 times a year, the company argues that it removes a major psychological barrier and improves patients’ quality of life.

Physicians’ Perspectives

Delhi‑based endocrinologist Dr. Anoop Misra highlighted the convenience factor: “Fewer needle pricks could encourage patients who have been hesitant to start insulin.” However, he cautioned that the drug does not constitute a wholesale replacement for daily therapy.

Dr. Shashank Joshi of Lilavati Hospital added that ongoing glucose monitoring remains essential and that the weekly formulation is best suited for patients willing to adopt digital health tools for diabetes management.

Who Stands to Benefit?

KEM Hospital’s endocrinologist Dr. Tushar Bandgar, who led one of the Indian trial sites, explained that Awiqli is most appropriate for individuals who still produce some endogenous insulin and only need basal supplementation. “Patients requiring multiple daily bolus doses may see limited advantage,” he noted.

Broader Therapeutic Landscape

Dr. Bandgar also pointed out that newer weight‑loss agents and GLP‑1 receptor agonists are already reducing insulin reliance for many patients. “While once‑weekly insulin is an important advance, the pool of patients needing basal insulin may gradually shrink,” he warned. Consequently, the drug is viewed as an additional tool rather than a universal solution.

Future Implications

As technology‑enabled diabetes care expands, the real-world impact of weekly insulin will hinge on patient selection, adherence to monitoring protocols, and integration with emerging therapies. If adopted wisely, Awiqli could streamline treatment for a subset of patients while prompting a re‑evaluation of insulin‑centric strategies across the country.